International randomized phase II trial of the combination of Vincristine and Irinotecan with or without Temozolomide (VI or VIT) in children and adults with refractory or relapsed rhabdomyosarcoma.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 03 Jan 2018
At a glance
- Drugs Temozolomide (Primary) ; Irinotecan; Vincristine
- Indications Rhabdomyosarcoma
- Focus Therapeutic Use
- 02 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 19 Jul 2017 Planned End Date changed from 31 Dec 2021 to 1 Sep 2021.
- 15 Mar 2017 Planned End Date changed from 1 Jun 2015 to 31 Dec 2021.